Innoviva Total Assets 2006-2019 | INVA

Innoviva total assets from 2006 to 2019. Total assets can be defined as the sum of all assets on a company's balance sheet.
Innoviva Annual Total Assets
(Millions of US $)
2019 $725
2018 $548
2017 $367
2016 $379
2015 $409
2014 $522
2013 $681
2012 $369
2011 $259
2010 $331
2009 $181
2008 $236
2007 $162
2006 $262
2005 $225
Innoviva Quarterly Total Assets
(Millions of US $)
2019-12-31 $725
2019-09-30 $676
2019-06-30 $642
2019-03-31 $590
2018-12-31 $548
2018-09-30 $278
2018-06-30 $339
2018-03-31 $277
2017-12-31 $367
2017-09-30 $391
2017-06-30 $372
2017-03-31 $392
2016-12-31 $379
2016-09-30 $371
2016-06-30 $378
2016-03-31 $388
2015-12-31 $409
2015-09-30 $438
2015-06-30 $462
2015-03-31 $489
2014-12-31 $522
2014-09-30 $554
2014-06-30 $606
2014-03-31 $605
2013-12-31 $681
2013-09-30 $666
2013-06-30 $595
2013-03-31 $592
2012-12-31 $369
2012-09-30 $384
2012-06-30 $399
2012-03-31 $218
2011-12-31 $259
2011-09-30 $283
2011-06-30 $303
2011-03-31 $315
2010-12-31 $331
2010-09-30 $213
2010-06-30 $232
2010-03-31 $250
2009-12-31 $181
2009-09-30 $183
2009-06-30 $206
2009-03-31 $215
2008-12-31 $236
2008-09-30 $255
2008-06-30 $281
2008-03-31 $300
2007-12-31 $162
2007-09-30 $199
2007-06-30 $208
2007-03-31 $248
2006-12-31 $262
2006-09-30 $292
2006-06-30 $319
2006-03-31 $327
2005-12-31 $225
2005-09-30 $197
2005-06-30 $234
2005-03-31 $259
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.170B $0.261B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $353.719B 15.46
Roche Holding AG (RHHBY) Switzerland $281.610B 0.00
Merck (MRK) United States $193.391B 14.69
Novartis AG (NVS) Switzerland $191.686B 15.96
Pfizer (PFE) United States $186.623B 11.40
Novo Nordisk (NVO) Denmark $141.701B 24.33
Eli Lilly (LLY) United States $133.660B 23.12
Bristol-Myers Squibb (BMY) United States $125.360B 11.89
AstraZeneca (AZN) United Kingdom $115.367B 24.84
Sanofi (SNY) France $112.261B 13.34
AbbVie (ABBV) United States $108.343B 8.21
GlaxoSmithKline (GSK) United Kingdom $92.675B 11.75
Bayer (BAYRY) Germany $53.491B 7.71
H Lundbeck (HLUYY) Denmark $5.974B 10.38